The Day In Review: AstraZeneca PLC Enters Two Partnerships

January 31, 2007 -- AstraZeneca signed two drug development deals, one with Argenta Discovery for chronic obstructive pulmonary disease, and the other with Palatin for obesity; Curis and Genentech began a Phase I test of a Hedgehog antagonist for cancer; Pharmion said the FDA accepted its IND for an oral formulation of azacitidine; Avanir received an approvable letter for an orally disintegrating form of FazaClo, or clozapine; and Sepracor handily beat estimates for Q4 but warned revenues would slip in the first half of 2007. The Centient Biotech 200™ rose 8 points to 4042, an increase of .20%. More details...